A senior member of Verona Pharma PLC’s (LON:VRP, NASDAQ:VRNA) scientific team will expand on symptom data from a phase IIb clinical trial of its inhaled drug for chronic obstructive pulmonary disease (COPD).
Chief medical officer Kathleen Rickard will present the new information on nebulised ensifentrine at the CHEST Annual Meeting, being held in New Orleans, next Monday, October 21.
Verona’s second-stage study revealed the treatment to provide “clinically meaningful improvements” in both lung function and symptoms, including breathlessness, in people with moderate-to-severe COPD. It has been well-tolerated in clinical trials involving more than 800 people to date.
COPD is a respiratory disease, which is progressive and life-threatening and is caused by long-term exposure to lung irritants such as tobacco smoke.
The cost of treatment in the US alone is put at US$49bn annually.